SURI Simplify Propel Opportunities ETF

ETF on NYSE (US) · Actively managed · Listing

Daily holdings file Nov 17, 2026 Published at simplify.us
Book $68.1M 38 positions
Line items 38
In top 10 84%
Largest holding: Plains GP Holdings, L.P. ($22.2M) 32.6%
Portfolio date Nov 17, 2026

Changes appear once four weeks of holdings are on file.

Largest holding: Plains GP Holdings, L.P., 846,388 shares ($22.2M).

Plains GP Holdings, L.P.: 32.6% SIMPLIFY E GOVT MONEY MKT ETF: 15.8% Achieve Life Sciences, Inc.: 8.4% Cash: 6.5% Delcath Systems, Inc.: 5.9% ACHIEVE LIFE SCIENCES I WTS 30JUN30: 4.4% Collegium Pharmaceutical, Inc.: 3.5% Orchestra BioMed Holdings, Inc.: 2.5% Corcept Therapeutics Incorporated: 2.1% Milestone Pharmaceuticals Inc.: 2.0% The other 28 positions: 16.3% $68.1M Holdings value
Current positions Top 10 % of book
Plains GP Holdings, L.P. PAGP $22.2M 32.6%
SIMPLIFY E GOVT MONEY MKT ETF SBIL $10.8M 15.8%
Achieve Life Sciences, Inc. ACHV $5.70M 8.4%
Cash CASH $4.43M 6.5%
Delcath Systems, Inc. DCTH $4.03M 5.9%
ACHIEVE LIFE SCIENCES I WTS 30JUN30 $3.02M 4.4%
Collegium Pharmaceutical, Inc. COLL $2.39M 3.5%
Orchestra BioMed Holdings, Inc. OBIO $1.69M 2.5%
Corcept Therapeutics Incorporated CORT $1.44M 2.1%
Milestone Pharmaceuticals Inc. MIST $1.38M 2.0%

Slices are % of holdings value.

Healthcare: 37.9% Energy: 32.6% Unclassified: 29.5% 2 sectors
Sectors % of holdings value
Healthcare 37.9%
Energy 32.6%
Unclassified 29.5%
Oil & Gas Midstream: 32.6% Biotechnology: 16.1% Drug Manufacturers - Specialty & Generic: 11.9% Medical Devices: 8.4% Drug Manufacturers - General: 1.5% Unclassified: 29.5% 5 industries
Industries % of holdings value
Oil & Gas Midstream 32.6%
Biotechnology 16.1%
Drug Manufacturers - Specialty & Generic 11.9%
Medical Devices 8.4%
Drug Manufacturers - General 1.5%
Unclassified 29.5%

Source: the fund's own published holdings, the portfolio of Nov 17, 2026 (simplify.us). Cash and money-market lines are in the book and its value but are never counted as trades. Short positions are listed as such, at their (negative) printed value.

Objective

The Simplify Propel Opportunities ETF (the "Fund" or "SURI") seeks long-term capital appreciation.

Principal investment strategies

The Fund is an actively managed exchange-traded fund ("ETF"). The Fund's investment adviser Simplify Asset Management Inc. (the "Adviser") collaborates with the Fund's sub-adviser, Propel Bio Management, LLC (the "Sub-Adviser"), to seek to achieve the Fund's investment objective. The Fund concentrates its investments (i.e., invests more than 25% of its net assets) in the securities of issuers in the biotechnology, pharmaceuticals, healthcare technology, and life science tools and services industries. Each of these industries are commonly categorized within the healthcare sector because they share similar economic features and regulatory constraints. The Fund also may invest in securities of issuers engaged in energy-related endeavors such as the production, generation, and sale of energy resources. The Sub-Adviser employs an actively managed opportunistic multi-asset strategy that focuses on common stock, preferred stock, convertible bonds, structured notes, corporate notes and bonds, and ETFs that primarily invest in the preceding security types. The Fund also may invest in money market funds. The Adviser employs a derivatives strategy to partially protect or enhance Fund returns. The Sub-Adviser is responsible for security selection and the Adviser is responsible for trade execution, regulatory oversight of the Fund and the derivatives strategy. The Fund invests without restriction as to security currency, issuer capitalization (including micro-capitalization), or country and without restriction as to debt credit quality, maturity, structure, or issuer type. Lower quality corporate debt is commonly known as a "junk bond." Junk bonds are generally rated lower than Baa3 by Moody's Investors Service, Inc. or lower than BBB- by Standard and Poor's Ratings Group or lower than BBB- by Fitch Ratings, Inc. The Fund may invest in privately placed and restricted securities (including 144A bonds). The Fund is classified as a "non-diversified" fund under the Investment Company Act of 1940, as amended, which means that the Fund may invest a higher percentage of its assets in a fewer number of issuers than is permissible for a "diversified" Fund. Sub-Adviser's Opportunistic Multi-Asset Strategy The Sub-Adviser selects securities that it believes present attractive investment opportunities, which may include securities that the Sub-Adviser believes are neglected and overlooked investments and present significant opportunities for capital appreciation. The Sub-Adviser uses fundamental, bottom-up analysis to identify securities that present attractive investment opportunities, which may include securities that the Sub-Adviser determines to be undervalued or present opportunities for growth. The Sub-Adviser selects debt or equity exposure based on its estimation of expected relative returns. The Sub-Adviser sells a security when it believes it is no longer undervalued or when more attractive investments are identified. Healthcare Sector Sub-Strategy The Sub-Adviser employs individuals who possess significant scientific, technical, operational, regulatory and commercial expertise to evaluate the science and prospects of healthcare sector companies as well as individuals with significant experience and expertise in identifying securities that present attractive investment opportunities, which may include securities that the Sub-Adviser determines to be undervalued or present opportunities for growth. Healthcare sector companies that the Fund typically includes in the portfolio are small to medium capitalization companies that may be in various stages of maturity. These may include "early-stage companies" which include those that routinely develop new products or services or are in the process of conducting clinical trials and may not yet be consistently profitable.

Management and Contact

Adviser
Simplify Asset Management Inc.
Sub-adviser
Propel Bio Management, LLC
Portfolio managers

David Berns, PhD, Chief Investment Officer of the Adviser;

Jeff Schwarte, Chief Equity Strategist of the Adviser, Leen Kawas, Managing General Partner of the Sub-Adviser; and Xue Hua, Portfolio Manager of the Sub-Adviser; serve as portfolio managers for the Fund.

Dr. Berns, Ms. Kawas, and Ms. Hua have each served the Fund as a portfolio manager since December 2022.

Mr. Schwarte has served the Fund as a portfolio manager since November 2024.

Dr. Berns, Mr. Schwarte, Ms. Kawas, and Ms. Hua, are jointly and primarily responsible for the management of the Fund.

Phone
(855) 772-8488

Track Record as of Dec 31, 2025

1 Year Since Inception
Return Before Taxes 25.10% 2.51%
Return After Taxes on Distributions 16.88% -3.98%
Return After Taxes on Distributions and Sale of Fund Shares 14.29% -0.93%
MSCI USA IMI Health Care Net Total Return USD Index (reflects no deduction for fees, expenses or taxes) 14.91% 6.88%
S&P 500 Index (reflects no deduction for fees, expenses or taxes) 17.88% 20.45%

Holdings as of Nov 17, 2026

38 lines, 23 linked, weights sum to 100.01% · Actively managed (N-CEN)

Holding Ticker / identifier Type Shares Change Weight Market value
PLAINS GP HLDGS L P PAGP US72651A2078 Equity 846,388 0 32.57% $ 22.184M
SIMPLIFY E GOVT MONEY MKT ETF SBIL US82889N2696 Fund 107,300 0 15.79% $ 10.758M
ACHIEVE LIFE SCIENCES INC USD 0.001 QUIT US0044685008 Equity 932,105 0 8.37% $ 5.704M
Cash
CASH Cash 4,434,130.9441 โˆ’1,492.4886 6.51% $ 4.434M
DELCATH SYS INC USD 0.01 DCTH US24661P8077 Equity 207,999 0 5.92% $ 4.029M
ACHIEVE LIFE SCIENCES I WTS 30JUN30
US0044681874 Warrant 966,667 0 4.43% $ 3.016M
COLLEGIUM PHARMACEUTICAL USD 0.001 COLL US19459J1043 Equity 93,521 0 3.51% $ 2.389M
ORCHESTRA BIOMED HLDGS I USD 0.0001 OBIO US68572M1062 Equity 242,098 0 2.48% $ 1.687M
CORCEPT THERAPEUTICS INC USD 0.001 CORT US2183521028 Equity 20,568 0 2.12% $ 1.441M
MILESTONE PHARMACEUTICALS INC NPV MIST CA59935V1076 Equity 3,349,379 0 2.03% $ 1.384M
PHATHOM PHARMACEUTICALS USD 0.0001 PHAT US71722W1071 Equity 249,267 0 2.01% $ 1.371M
AQUESTIVE THERAPEUTICS IN USD 0.001 AQST US03843E1047 Equity 278,723 0 1.51% $ 1.031M
INVENTIVA SA NPV ADR IVA US46124U1079 Equity 311,468 0 1.47% $ 1.003M
KYVERNA THERAPEUTICS IN USD 0.00001 KYTX US5019761049 Equity 182,603 0 1.26% $ 858.234K
TELSAT 5.625 12/06/26 144A Corp
TELSAT 5.625 12/06/26 144A CORP US87952VAR78 Equity 1,000,000 0 1.22% $ 830K
COMPASS PATHWAYS PLC USD 0.008 ADR CMPS US20451W1018 Equity 90,381 0 1.06% $ 721.24K
ACHIEVE LIFE SCIENCES WTS
WTSACHV01 Warrant 247,593 0 0.95% $ 646.218K
CELLDEX THERAPEUTICS INC USD 0.001 CLDX US15117B2025 Equity 21,629 0 0.89% $ 606.477K
CABALETTA BIO INC USD 0.00001 CABA US12674W1099 Equity 556,235 0 0.83% $ 567.36K
PROKIDNEY CORP DEL USD 0.0001 PROK US74291D1046 Equity 483,741 0 0.78% $ 532.115K
OPUS GENETICS INC USD 0.0001 IRD US67577R1023 Equity 125,000 0 0.74% $ 506.25K
OCULAR THERAPEUTIX INC USD 0.0001 OCUL US67576A1007 Equity 81,051 0 0.72% $ 487.927K
PALISADE BIO INC USD 0.01 PALI US6963894026 Equity 434,333 0 0.64% $ 438.676K
AKERO THERAPEUTICS INC CVR
AKERO THERAPEUTICS INC CVR 009CVR044 Right 145,609 0 0.63% $ 426.634K
SAB BIOTHERAPEUTICS INC USD 0.0001 SABS US78397T2024 Equity 104,849 0 0.45% $ 309.305K
LEONABIO INC USD 0.0001 LONA US04746L2034 Equity 98,606 0 0.40% $ 272.153K
CORVUS PHARMACEUTICALS I USD 0.0001 CRVS US2210151005 Equity 25,000 0 0.37% $ 254.25K
IMMUNIC INC USD 0.0001 IMUX US4525EP2001 Equity 30,725 0 0.33% $ 225.214K
CONTRA CHINOOK THERAPE + NPV
US169CVR0169 Right 25,000 0 0.00% $ 2,000.00
EIGER BIOPHARMACEUTICALS USD 0.0001
EIGRQ US28249U2042 Equity 90,000 0 0.00% $ 900.00
WTS - MILESTONE PHARMACEUTICALS INC SERIES B
WTSMISTSB Warrant 1,842,974 0 0.00% $ 1.84
WTS - TENAYA THERAPEUTICS INC
WTSTNYA01 Warrant 560,000 0 0.00% $ 0.56
MOLECULIN BIOTECH INC WTS
WTSMBRX01 Warrant 50,000 0 0.00% $ 0.05
WTS - QUOIN PHARMACEUTICALS LTD - Series I
WTSQNRX03 Warrant 34,895 0 0.00% $ 0.03
WTS - QUOIN PHARMACEUTICALS LTD - Series K
WTSQNRX05 Warrant 34,895 0 0.00% $ 0.03
ALTIMMUNE INC
WTSALT001 Equity 79,075 0 0.00% $ 0.08
WTS - QUOIN PHARMACEUTICALS LTD - Series J
WTSQNRX04 Warrant 34,895 0 0.00% $ 0.03
WTS - QUOIN PHARMACEUTICALS LTD - Series H
WTSQNRX02 Warrant 34,895 0 0.00% $ 0.03

Trades Nov 16, 2026 to Nov 17, 2026

Holding Ticker Action Before After Change Value

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up